Hoda Pourhassan, M.D.

(877) 460-4673
Hoda Pourhassan, M.D.
Hematologist-Oncologist
Clinical Expertise
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Hematology & Hematopoietic Cell Transplantation
  • Immunotherapy
  • Allogenic Stem Cell Transplant
Research Area
  • Hematology and Hematopoietic Cell Transplantation
  • Leukemia
Other Languages Spoken
Farsi
Academic Appointments
  • Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation
Clinical Teams
Hematology & Hematopoietic Cell Transplantation
Leukemia
Research Teams
Leukemia Research
Hematology & Hematopoietic Cell Transplantation
For Hoda Z. Pourhassan, M.D., being a physician is where scientific curiosity meets humanity. She is a strong believer in City of Hope’s team approach to treatment, and infuses her care with insights gained from her research into the genetics of blood cancers.
 
Fluent in Farsi, Dr. Pourhassan earned her master’s in health administration and management and her medical degree at Rosalind Franklin University of Medicine and Science in Chicago. She began her postgraduate training with a residency at Hennepin County Medical Center in Minneapolis, during which she conducted research into stem cell transplantation at University of Minnesota. Dr. Pourhassan then served as chief resident at Riverside Community Hospital and clinical instructor at University of California Riverside. She has completed fellowships in oncology/hematology at Loma Linda University and in bone marrow transplantation and cellular therapy at City of Hope.

Location

Education & Experience

Degrees

  • 2013, Doctor of Medicine, Rosalind Franklin University, North Chicago, IL

  • 2010, Master of Science, Rosalind Franklin University, North Chicago, IL

Fellowship

  • 2020-2021, Fellow, Bone Marrow Transplant and Cellular Therapy,
    City of Hope, Duarte, CA

  • 2017-2020, Fellow, Hematology/Oncology, Loma Linda University, Loma Linda, CA

Residency

  • 2013-2016, Residency, Internal Medicine, Hennepin County Medical Center, Minneapolis, MN

Professional Experience

  • 2021-present, Assistant Professor, Division of Leukemia, Department of Hematology & Hematopoietic Transplantation,
    City of Hope, Duarte, CA

  • 2016-2021, Health Sciences Clinical Instructor, University of California Riverside School of Medicine, Riverside, CA

  • 2016-2017, Chief Resident, Riverside Community Hospital, Riverside, CA

Awards & Memberships

Memberships

  • American Society of Hematology

  • American Society of Clinical Oncology

  • Iranian Society for Protecting Rights of the Child

  • American College of Physicians

Publications

  • Pourhassan H, Agrawal V, Pullarkat V, Aldoss I. Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment. Front Oncol. 2023 Aug 17;13:1237031. doi: 10.3389/fonc.2023.1237031. PMID: 37664035; PMCID: PMC10470626.
  • Yao JM, Otoukesh S, Kim H, Yang D, Mokhtari S, Samara Y, Blackmon A, Arslan S, Agrawal V, Pourhassan H, Amanam I, Ball B, Koller P, Salhotra A, Becker P, Curtin P, Artz A, Aldoss I, Ali H, Stewart F, Smith E, Stein A, Marcucci G, Forman SJ, Nakamura R, Al Malki MM. Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis. Transplant Cell Ther. 2023 Aug;29(8):515.e1-515.e7. doi: 10.1016/j.jtct.2023.05.008. Epub 2023 May 12. PMID: 37182736.
  • Aldoss I, Afkhami M, Yang D, Gu Z, Mokhtari S, Shahani S, Pourhassan H, Agrawal V, Koller P, Arslan S, Tomasian V, Al Malki MM, Artz A, Salhotra A, Ali H, Aribi A, Sandhu KS, Ball B, Otoukesh S, Amanam I, Becker PS, Stewart FM, Curtin P, Smith E, Telatar M, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pullarkat V. High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions. Am J Hematol. 2023 Jun;98(6):848-856. doi: 10.1002/ajh.26908. Epub 2023 Mar 16. PMID: 36880203.
  • Agrawal V, Pourhassan H, Tsai NC, Ngo D, Koller P, Malki MMA, Salhotra A, Ali H, Aribi A, Sandhu KS, Arslan S, Ball B, Otoukesh S, Amanam I, Artz A, Singh D, Becker PS, Stewart FM, Smith EP, Curtin P, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pullarkat V, Aldoss I. Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab. Transplant Cell Ther. 2023 May;29(5):314-320. doi: 10.1016/j.jtct.2023.01.017. Epub 2023 Jan 19. PMID: 36682470.
  • Tanenbaum HC, Birmann BM, Bertrand KA, Teras LR, Krishnan AY, Pourhassan H, Goldsmith S, Cannavale K, Wang SS, Chao CR. Identifying monoclonal gammopathy of undetermined significance from electronic health records. Cancer Rep (Hoboken). 2023 Mar;6(3):e1755. doi: 10.1002/cnr2.1755. Epub 2022 Dec 4. PMID: 36464325; PMCID: PMC10026307.
  • Pourhassan H, Douer D, Pullarkat V, Aldoss I. Asparaginase: How to Better Manage Toxicities in Adults. Curr Oncol Rep. 2023 Jan;25(1):51-61. doi: 10.1007/s11912-022-01345-6. Epub 2022 Nov 30. PMID: 36449117.
  • Pourhassan H, Kim Y, Pullarkat V. Clearance of bone marrow mast cells after hypomethylating agent and venetoclax for systemic mastocytosis associated with myeloid neoplasia. Eur J Haematol. 2023 Feb;110(2):213-216. doi: 10.1111/ejh.13894. Epub 2022 Nov 15. PMID: 36335580; PMCID: PMC10099671.
  • Aldoss I, Pourhassan H, Douer D. SOHO State of the Art Updates and Next Questions | Asparaginase-Understanding and Overcoming Toxicities in Adults with ALL. Clin Lymphoma Myeloma Leuk. 2022 Nov;22(11):787-794. doi: 10.1016/j.clml.2022.08.009. Epub 2022 Aug 24. PMID: 36114134.
  • Ball BJ, Arslan S, Koller P, Ngo D, Afkhami M, Salhotra A, Al-Malki M, Aribi A, Ali H, Sandhu K, Otoukesh S, Amanam I, Pourhassan H, Artz A, Curtin P, Stein A, Nakamura R, Marcucci G, Smith E, Pullarkat V, Aldoss I. Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML). Leuk Lymphoma. 2022 Dec;63(13):3232-3236. doi: 10.1080/10428194.2022.2116934. Epub 2022 Sep 10. PMID: 36089918.
  • Pourhassan H, Yang D, Afkhami M, Pillai R, Ball B, Al Malki M, Salhotra A, Ali H, Artz A, Curtin P, Armenian S, Stein A, Forman SJ, Marcucci G, Pullarkat V, Nakamura R, Aldoss I. High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia. Am J Hematol. 2022 May;97(5):E171-E173. doi: 10.1002/ajh.26490. Epub 2022 Feb 11. PMID: 35132678.
  • Pourhassan HZ, Tryon D, Schaeffer B., et al. Autoimmune rhabdomyolysis and a multiorgan display of PD-1 inhibitor induced immune related adverse events during treatment of metastatic melanoma. Exp Hematol Oncol 8, 20 (2019)
  • Pourhassan H, DeFor T, Trottier B, et al. MDS Disease Characteristics, Not Donor Source, Predict Hematopoietic Stem Cell Transplant Outcomes. Bone marrow transplantation. 2017;52(4):532-538. doi:10.1038/bmt.2016.303.
  • Nozhat Z, Hedayati, M, Pourhassan H. Signaling pathways in Medullary Thyroid Carcinoma: Therapeutic Implications. International Journal of Endocrine Oncology, vol. 3, No. 4
  • Han JY, Miller S, Wolfe T, Pourhassan H, Jerome K. Cell Type-Specific Induction and Inhibition of Apoptosis by Herpes Simplex Virus Type 2 ICP10. Journal of Virology. 2009; 83: 2765-2769

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
5.0
Spend enough time with you
4.9
Provider explain in way you understand
4.9
Show respect for what you say
4.8
Provider listen carefully to you
4.8
Know important info medical history
4.8
Rate provider 0-10
4.7
Recommend this provider office
01/27/25
City of Hope saved my life with their treatment plan. This team is excellent in what they do and what they know. They are the best out there by FAR. - Verified patient